Drug intelligence / Profile preview

RLD2401

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral (based On Clinical Trial Administration)[3]

Overview

RLD2401 is a small molecule pharmaceutical product developed by Hanmi Company Limited. Its precise mechanism of action is currently unknown. The drug has not received regulatory approval in any country and does not have any approved indications or known adverse events reported in the public domain. It has been used as a reference drug (comparator) in clinical trials, notably as an active comparator to HCP1004 in studies evaluating efficacy and safety for chronic low back pain, where it was administered orally twice daily for 12 weeks[2][3][9]. No further pharmacological details or molecular targets are available.

Brand names: RLD2401RLD-2401RLD 2401
Other names: RLD-2401RLD2401RLD 2401

Beyond the preview

Go deeper on RLD2401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLD2401.

Explore the full profile